Journal of Clinical Oncology
Articles in this Issue
Contemporary patterns of treatment and outcomes in germ-cell tumors across a provincial cancer system: British Columbia Germ Cell Tumor Clinical Database.
603 Background: British Columbia (BC) provides centralized, province-wide management for germ-cell tumors (GCT) across a l...
Histologic predictors of clinically significant biochemical recurrence and PSA kinetics after radical prostatectomy.
398 Background: Radical prostatectomy (RP) is a key treatment for localized prostate cancer. However, 20–40% of patients e...
REJOICE-PanTumor01: A phase 2 signal-seeking study of raludotatug deruxtecan (R-DXd) in patients with advanced or metastatic gynecologic or genitourinary tumors.
TPS574 Background: Cadherin-6 (CDH6), a transmembrane protein involved in cell–cell adhesion and epithelial–mesenchymal tr...
Remodeling of the periprostatic adipose microenvironment in aggressive prostate cancer: Insights from a multi-institutional atlas-based geometric analysis.
389 Background: Periprostatic adipose tissue (PPAT) plays an increasingly recognized role in prostate cancer progression....
Cardio-kidney-metabolic syndrome and prostate cancer: Prognostic significance of higher stages for cardiovascular morbidity and mortality.
358 Background: Patients with prostate cancer (PC) face a significant burden of cardiovascular disease (CVD). The newly es...
Plasma cell-free DNA methylation as a predictive biomarker for hormonal therapy response in advanced prostate cancer.
235 Background: Androgen deprivation therapy (ADT) plus androgen receptor pathway inhibitors (ARPI) is standard for advanc...
ARTEMIS-003: A phase 2 study of HS-20093 (GSK5764227) in patients with metastatic castration-resistant prostate cancer (mCRPC).
150 Background: B7 homolog 3 protein (B7-H3) is a promising therapeutic target in solid tumors including prostate cancer....
Temporal and racial patterns in prostate cancer stage migration following USPSTF PSA screening policy changes: A SEER 2005–2022 analysis.
42 Background: The U.S. Preventive Services Task Force (USPSTF) revised its prostate-specific antigen (PSA) screening reco...
Efficacy and safety of Lu-177-DGUL in a phase 2 study of patients with metastatic castration-resistant prostate cancer (mCRPC).
209 Background: Prostate-specific membrane antigen (PSMA) is an integral membrane protein highly specific to the prostate....
Association between prostate cancer and mental health: A comparison across cancer types using the Medical Expenditure Panel Survey, 2017–2022.
132 Background: Mental health is a critical yet often underrecognized dimension of cancer survivorship, influencing qualit...
Comparative efficacy of immune checkpoint inhibitor combination therapies by metastatic site in metastatic renal cell carcinoma.
440 Background: To retrospectively evaluate the differential efficacy of immuno-oncology (IO)-IO and IO-tyrosine kinase in...
Diabetic retinopathy as a marker for renal cell carcinoma among patients with type 2 diabetes mellitus.
486 Background: Type 2 diabetes mellitus (T2DM) has been associated with increased risk of renal cell carcinoma (RCC). Ani...
Structural classification of FOXA1 alterations and their association with clinical outcomes in prostate cancer patients: A multi-institutional retrospective analysis.
256 Background: FOXA1 is a transcription factor with gene alterations in 10-15% of prostate cancers. Due to its complex dy...
Patient (pt) preferences for treatment (tx) of non-metastatic hormone-sensitive prostate cancer (nmHSPC): A discrete choice experiment (DCE).
338 Background: Prostate cancer tx guidelines recommend androgen receptor pathway inhibitors (ARPI) ± androgen-deprivation...
Age as modifier of early proteomic remodeling after androgen deprivation therapy (ADT) in prostate cancer: Influence of innate immune/complement–ECM pathways.
246 Background: ADT is standard for advanced prostate cancer (PC) but increases cardiometabolic risk. The proteomic mechan...
Leveraging large language models (LLM) to guide adjuvant treatment recommendations for renal cell carcinoma (RCC) after nephrectomy.
567 Background: Selecting adjuvant therapy after nephrectomy for renal cell carcinoma (RCC) requires reviewing scattered e...
Real-world effectiveness and safety of first-line (1L) avelumab + axitinib (ave + axi) in patients with advanced renal cell carcinoma (aRCC): Final analysis of the prospective AVION study.
438 Background: In the JAVELIN Renal 101 phase 3 trial, 1L Ave + Axi significantly prolonged progression-free survival (PF...
Association between genomic classifier scores and initial management of localized prostate cancer in a population-based cohort in the United States.
350 Background: Tissue-based gene expression assays provide prognostic information in prostate cancer, but their independe...
ECOG ACRIN EA8192 cohort C: A phase II trial of neoadjuvant gemcitabine/durvalumab in patients (pts) with high grade (HG) upper tract urothelial carcinoma (UTUC) ineligible for cisplatin-based chemotherapy.
749 Background: There is mounting data for neoadjuvant chemotherapy use in HG UTUC, but the role of neoadjuvant chemoimmun...
Sasanlimab plus bacillus Calmette-Guérin in BCG-naive, high-risk non–muscle-invasive bladder cancer (NMIBC): Exploratory biomarker analysis of the phase 3 CREST trial.
806 Background: The primary analysis of the phase 3 CREST trial (NCT04165317), evaluating sasanlimab, a PD-1 inhibitor, co...
Clinical characteristics and survival outcomes of primary sarcoma of the kidney (PSK).
566 Background: Primary sarcoma of the kidney (PSK) is a rare malignancy. Clinical characteristics and survival outcomes o...
Genetic ancestry and stage-specific differences in prostate cancer genomic alterations.
262 Background: Men of African ancestry have higher prostate cancer-specific mortality than men of European ancestry. Soci...
Safety data from UPLIFT: Phase I/II study of CDK4/6 inhibition with abemaciclib to upregulate PSMA expression prior to <sup>177</sup> Lu-PSMA-617 treatment in patients with metastatic castrate resistant prostate cancer (mCRPC).
163 Background: 177 Lu-PSMA-617, a PSMA-targeting radioligand therapy, has shown robust responses in p...
Clinical outcomes of neoadjuvant chemotherapy–guided bladder preservation in muscle-invasive bladder cancer: Long-term results of a phase II trial.
742 Background: Radical cystectomy (RC) remains the standard of care for muscle-invasive bladder cancer (MIBC), yet it pro...
A phase II study of lutetium-177 DOTATATE in metastatic prostate cancer with neuroendocrine differentiation.
TPS292 Background: Neuroendocrine differentiated prostate cancer (NED PCa) is an aggressive form of prostate cancer with f...